178 related articles for article (PubMed ID: 34337534)
1. Sexual Dimorphism in Outcomes of Non-muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint.
Chenard S; Jackson C; Vidotto T; Chen L; Hardy C; Jamaspishvilli T; Berman D; Siemens DR; Koti M
Eur Urol Open Sci; 2021 Jul; 29():50-58. PubMed ID: 34337534
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer.
Hamade A; Li D; Tyryshkin K; Xu M; Conseil G; Yolmo P; Hamilton J; Chenard S; Robert Siemens D; Koti M
Biol Sex Differ; 2022 May; 13(1):19. PubMed ID: 35505436
[TBL] [Abstract][Full Text] [Related]
3. Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies.
Viveiros N; Flores BC; Lobo J; Martins-Lima C; Cantante M; Lopes P; Deantonio C; Palu C; Sainson RC; Henrique R; Jerónimo C
Clin Transl Immunology; 2022; 11(9):e1402. PubMed ID: 36092481
[TBL] [Abstract][Full Text] [Related]
4. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
[TBL] [Abstract][Full Text] [Related]
5. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
[TBL] [Abstract][Full Text] [Related]
6. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
9. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
10. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of cell cycle protein p53 expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer.
Aljabery F; Shabo I; Saudi A; Holmbom M; Olson H; Jahnson S
Urol Oncol; 2023 Mar; 41(3):148.e9-148.e16. PubMed ID: 36702703
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
[TBL] [Abstract][Full Text] [Related]
13. Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.
Aragaki AK; Jing Y; Hoffman-Censits J; Choi W; Hahn NM; Trock BJ; McConkey DJ; Johnson BA
Eur Urol Oncol; 2022 Jun; 5(3):338-346. PubMed ID: 34426176
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
[TBL] [Abstract][Full Text] [Related]
15. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.
Kostine M; Briaire-de Bruijn IH; Cleven AHG; Vervat C; Corver WE; Schilham MW; Van Beelen E; van Boven H; Haas RL; Italiano A; Cleton-Jansen AM; Bovée JVMG
Oncoimmunology; 2018; 7(2):e1386828. PubMed ID: 29308311
[No Abstract] [Full Text] [Related]
16. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
[TBL] [Abstract][Full Text] [Related]
18. Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment.
Besançon M; Gris T; Joncas FH; Picard V; Bergeron A; Fradet Y; Toren P
Eur Urol Open Sci; 2022 Sep; 43():35-44. PubMed ID: 36246841
[TBL] [Abstract][Full Text] [Related]
19. OncoTherad
Reis IB; Tibo LHS; de Souza BR; Durán N; Fávaro WJ
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5025-5036. PubMed ID: 36322290
[TBL] [Abstract][Full Text] [Related]
20. Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment.
Koti M; Ingersoll MA; Gupta S; Lam CM; Li X; Kamat AM; Black PC; Siemens DR
Eur Urol Oncol; 2020 Oct; 3(5):622-630. PubMed ID: 32967818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]